Walleye Capital LLC Acquires New Shares in Dianthus Therapeutics, Inc. $DNTH

Walleye Capital LLC acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 17,881 shares of the company’s stock, valued at approximately $1,743,000.

Other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its holdings in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. State Street Corp lifted its holdings in shares of Dianthus Therapeutics by 124.7% during the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after purchasing an additional 836,571 shares in the last quarter. Polar Capital Holdings Plc purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at $29,434,000. Finally, Marshall Wace LLP purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at $22,545,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $115.96 on Friday. The stock has a market capitalization of $6.34 billion, a price-to-earnings ratio of -27.94 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 1-year low of $19.84 and a 1-year high of $116.47. The business’s fifty day moving average price is $97.47 and its 200-day moving average price is $82.85.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Analyst Ratings Changes

DNTH has been the subject of several research analyst reports. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $124.27.

Insider Buying and Selling

In other Dianthus Therapeutics news, CEO Marino Garcia sold 166,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the sale, the chief executive officer directly owned 65,292 shares in the company, valued at $7,058,718.12. The trade was a 71.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $362,480. The trade was a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 284,306 shares of company stock valued at $29,289,369 in the last 90 days. Insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.